SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001144204-18-033468
Filing Date
2018-06-08
Accepted
2018-06-08 13:39:26
Documents
3
Period of Report
2018-06-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tv496024_8k.htm 8-K 21363
2 EXHIBIT 99.1 tv496024_ex99-1.htm EX-99.1 10348
3 GRAPHIC image_001.jpg GRAPHIC 13864
  Complete submission text file 0001144204-18-033468.txt   52261
Mailing Address 550 SYLVAN AVENUE, SUITE 101 ENGLEWOOD CLIFFS NJ 07632
Business Address 550 SYLVAN AVENUE, SUITE 101 ENGLEWOOD CLIFFS NJ 07632 201-464-2677
IMMUNE PHARMACEUTICALS INC (Filer) CIK: 0001208261 (see all company filings)

IRS No.: 521841431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36602 | Film No.: 18888914
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences